PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.

DNA repair PARP inhibitors homologous recombination repair prostate cancers

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
21 Mar 2022
Historique:
received: 04 02 2022
revised: 07 03 2022
accepted: 14 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 26 3 2022
Statut: epublish

Résumé

Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular

Identifiants

pubmed: 35330059
pii: jcm11061734
doi: 10.3390/jcm11061734
pmc: PMC8952857
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

N Engl J Med. 2020 Dec 10;383(24):2345-2357
pubmed: 32955174
J Hematol Oncol. 2021 Mar 29;14(1):51
pubmed: 33781305
J Clin Oncol. 2019 Feb 20;37(6):490-503
pubmed: 30625039
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
Lancet Oncol. 2022 Mar;23(3):362-373
pubmed: 35131040
Lancet Oncol. 2018 Jul;19(7):975-986
pubmed: 29880291
Clin Cancer Res. 2020 Jun 1;26(11):2487-2496
pubmed: 32086346
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
BMC Genomics. 2005 Oct 04;6:139
pubmed: 16202152
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Prostate. 2014 Feb;74(2):210-6
pubmed: 24132735
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Am J Kidney Dis. 2020 Dec;76(6):898-900
pubmed: 32679152
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
Cancers (Basel). 2021 Nov 20;13(22):
pubmed: 34830984
Xenobiotica. 2017 Oct;47(10):903-915
pubmed: 27684210
Nat Commun. 2017 Aug 29;8(1):374
pubmed: 28851861
Eur Urol. 2017 May;71(5):740-747
pubmed: 27989354
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
Mol Cell Biol. 2004 Jan;24(2):708-18
pubmed: 14701743
Lancet Oncol. 2015 Jan;16(1):87-97
pubmed: 25481791
Sci Signal. 2017 May 23;10(480):
pubmed: 28536297
JAMA Oncol. 2021 Jun 4;:
pubmed: 34086042
Mod Pathol. 2016 Dec;29(12):1460-1470
pubmed: 27562496
J Pathol Clin Res. 2021 Jul;7(4):311-325
pubmed: 33630412
J Cell Biol. 2012 Oct 15;199(2):235-49
pubmed: 23045548
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Cancer Res. 2021 Jan 15;27(2):566-574
pubmed: 32988971
Biopreserv Biobank. 2013 Apr;11(2):101-6
pubmed: 24845430
Xenobiotica. 2020 Sep;50(9):1032-1042
pubmed: 32129697
Genes Dev. 2017 Feb 1;31(3):318-332
pubmed: 28242626
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
Nat Struct Mol Biol. 2010 Oct;17(10):1260-2
pubmed: 20729859
Lancet Haematol. 2021 Feb;8(2):e122-e134
pubmed: 33347814
Lancet Oncol. 2022 Mar;23(3):393-405
pubmed: 35157830
Mol Cancer Res. 2009 Jul;7(7):1110-8
pubmed: 19584259
JCO Precis Oncol. 2020;4:370-381
pubmed: 32462107
Cancer Discov. 2013 Nov;3(11):1245-53
pubmed: 24027196
Nat Genet. 2018 May;50(5):682-692
pubmed: 29662167
Clin Cancer Res. 2011 Feb 1;17(3):401-5
pubmed: 21088254
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
J Clin Oncol. 2020 Aug 20;38(24):2798-2811
pubmed: 32516092
J Clin Oncol. 2017 Jan;35(1):40-47
pubmed: 28034081
Mol Cell Biol. 2003 Jun;23(11):3974-81
pubmed: 12748298
JAMA Oncol. 2021 Jan 1;7(1):107-110
pubmed: 33151258
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Lancet Oncol. 2020 Jan;21(1):162-174
pubmed: 31806540
J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6
pubmed: 10433620
J Clin Invest. 2020 Apr 1;130(4):1743-1751
pubmed: 31874108
Prostate. 2018 Jun;78(8):607-615
pubmed: 29520813
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
Nat Commun. 2020 Jul 24;11(1):3726
pubmed: 32709856
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Cancer Discov. 2012 Dec;2(12):1134-49
pubmed: 22993403
Hum Mol Genet. 2001 Oct 1;10(20):2253-9
pubmed: 11673408
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
J Pharmacol Exp Ther. 2014 Jun;349(3):408-16
pubmed: 24650937
J Clin Invest. 2019 Mar 1;129(3):1211-1228
pubmed: 30589644
Clin Cancer Res. 2022 Jan 28;:
pubmed: 35091440
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
Eur Urol. 2019 Apr;75(4):667-675
pubmed: 30638634

Auteurs

Diego Teyssonneau (D)

Department of Medical Oncology, Institut Bergonié, 33000 Bordeaux, France.

Antoine Thiery-Vuillemin (A)

Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, 25000 Besançon, France.

Charles Dariane (C)

Department of Urology, Hôpital Européen Georges-Pompidou, AP-HP, Paris University, 75005 Paris, France.

Eric Barret (E)

Department of Urology, Institut Mutualiste Montsouris, 75014 Paris, France.

Jean-Baptiste Beauval (JB)

Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, 31000 Toulouse, France.

Laurent Brureau (L)

Department of Urology, CHU de Pointe-à-Pitre, University of Antilles, 97110 Pointe-à-Pitre, France.

Gilles Créhange (G)

Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, 38400 Grenoble, France.

Gaëlle Fiard (G)

Department of Radiation Oncology, Curie Institute, 75005 Paris, France.

Gaëlle Fromont (G)

Department of Pathology, CHRU Tours, 37000 Tours, France.

Mathieu Gauthé (M)

Department of Nuclear Medicine, Scintep, 38000 Grenoble, France.

Alain Ruffion (A)

Service d'Urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69000 Lyon, France.
Equipe 2, Centre d'Innovation en Cancérologie de Lyon (EA 3738 CICLY), Faculté de Médecine Lyon Sud, Université Lyon 1, 69000 Lyon, France.

Raphaële Renard-Penna (R)

Department of Radiology, Sorbonne University, AP-HP, Radiology, Pitie-Salpetriere Hospital, 75013 Paris, France.

Romain Mathieu (R)

Department of Urology, University of Rennes, 35000 Rennes, France.
Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail), University of Rennes, 35000 Rennes, France.

Paul Sargos (P)

Department of Radiotherapy, Institut Bergonié, 33000 Bordeaux, France.

Morgan Rouprêt (M)

Department of Urology, Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, 75013 Paris, France.

Guillaume Ploussard (G)

Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, 31000 Toulouse, France.

Guilhem Roubaud (G)

Department of Medical Oncology, Institut Bergonié, 33000 Bordeaux, France.

Classifications MeSH